Care routes
An online visit is still a medical visit. Compare who reviews your health, what they ask, and how you get help afterward.
A live visit makes it easy to explain a concern in your own words. The doctor or other licensed medical professional can ask a new question at once.
Video can also help when appearance or movement matters. A later test or in-person exam may still be needed.
A video visit must meet the same medical rules as an in-person visit. If the needed care cannot be provided safely by video, it should be done another way.
With a form reviewed later, the patient and medical professional do not take part at the same time.
A first visit does not always need live video. Before deciding whether a medicine fits, the review should cover health conditions, current medicines, allergies, pregnancy plans, and any surgery coming up.
A form must let the medical professional ask follow-up questions or request more history when an answer raises a new issue.
Phone calls can help when video is not available or does not add value. State rules differ on when audio alone is enough.
As of September 2026, there was no single American rule for online prescribing. Each state set its own terms.
A screen cannot perform a physical exam or draw blood. A virtual service can arrange testing or refer to local care when the review calls for it.
That handoff is not a failure of virtual care. It is part of knowing when the format has reached its limit.
As of September 2026, the medical professional needed a licence or other state permission where the patient was located during the visit.
An office in another state is not the problem. Missing permission to treat a patient in their state is the problem.
The state medical board is the public place to check a doctor’s licence and discipline record.
As of September 2026, Ozempic and Wegovy were FDA-approved brands for named uses. Their labels covered benefits, side effects, and warnings.
Brand and form matter. Ozempic and Wegovy share semaglutide, but their approved uses are not the same.
This is medicine made to order by a pharmacy or doctor. It can fill a specific patient need that an approved product cannot meet.
As of September 2026, compounded medicines were not FDA-approved, and the FDA did not check each one for safety, effect, or quality before marketing.
As of September 2026, semaglutide injections were not on the FDA’s national shortage list.
The FDA said the injection shortage ended on February 21, 2025. It then gave compounding pharmacies until later that spring to finish the near-copies that shortage rules had allowed.
As of September 2026, federal law did not make every made-to-order prescription illegal. It allowed one when the person writing the prescription decided a change would make a significant difference for that patient, such as removing a dye the patient cannot take.
As of September 2026, the FDA said a compounded copy being cheaper or easier to use did not count as a medical need for making it.